Log in

CNSX:HUGEFSD Pharma Stock Price, Forecast & News

-0.13 (-2.48 %)
(As of 07/3/2020 01:09 PM ET)
Today's Range
Now: $5.12
50-Day Range
MA: $5.14
52-Week Range N/A
Volume5,384 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
FSD Pharma Inc. operates as a cannabis company in Canada. It is involved in hydroponic indoor cannabis production and processing activities. The company, through its subsidiary, FV Pharma Inc., holds license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations. It has a strategic alliance agreement with SciCann Therapeutics Inc. for the production and distribution of cannabinoid-based, patent pending, and indication-specific products developed by SciCann Therapeutics Inc. The company was formerly known as Century Financial Capital Group Inc. and changed its name to FSD Pharma Inc. in May 2018. FSD Pharma Inc. was incorporated in 1994 and is headquartered in Cobourg, Canada.
Read More
FSD Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.74 out of 5 stars

Industry, Sector and Symbol

Industry Software - Application



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive HUGE News and Ratings via Email

Sign-up to receive the latest news and ratings for HUGE and its competitors with MarketBeat's FREE daily newsletter.

FSD Pharma (CNSX:HUGE) Frequently Asked Questions

Has FSD Pharma been receiving favorable news coverage?

Media coverage about HUGE stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. FSD Pharma earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about FSD Pharma.

Who are some of FSD Pharma's key competitors?

What other stocks do shareholders of FSD Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FSD Pharma investors own include Aurora Cannabis (ACB), Canopy Growth (WEED), Canopy Growth (CGC), Cannara Biotech (LOVE), Aphria (APHA), Aurora Cannabis (ACB), Aphria (APHA), Bombardier, Inc. Class B (BBD.B), AutoCanada (ACQ) and ARC Resources (ARX).

What is FSD Pharma's stock symbol?

FSD Pharma trades on the CNSX under the ticker symbol "HUGE."

How do I buy shares of FSD Pharma?

Shares of HUGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is FSD Pharma's stock price today?

One share of HUGE stock can currently be purchased for approximately $5.12.

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.